Tau Proteins in the Temporal and Frontal Cortices in Patients With Vascular Dementia

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Neuropathology and Experimental Neurology

• Publication date

  2015-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/NEN.0000000000000157PMID 25575131
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A critical analysis of the 'amyloid cascade hypothesis'.

  2014cited by this paper
• MARK4 and MARK3 associate with early tau phosphorylation in Alzheimer’s disease granulovacuolar degeneration bodies

  2014cited by this paper
• Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease

  2014cited by this paper
• Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre.

  2013cited by this paper
• Tangles, Toxicity, and Tau Secretion in AD – New Approaches to a Vexing Problem

  2013cited by this paper
• Genetic Loci Associated with Alzheimer’s Disease and Cerebrospinal Fluid Biomarkers in a Finnish Case-Control Cohort

  2013cited by this paper
• Tau Protein Diffuses along the Microtubule Lattice*

  2012cited by this paper
• Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort

  2012cited by this paper
• Effects of systolic blood pressure on white-matter integrity in young adults in the Framingham Heart Study: a cross-sectional study.

  2012cited by this paper
• Genetic evidence that vascular dementia is related to Alzheimer's disease: genetic association between tau polymorphism and vascular dementia in the Chinese population.

  2011cited by this paper
• Exosome-associated Tau Is Secreted in Tauopathy Models and Is Selectively Phosphorylated in Cerebrospinal Fluid in Early Alzheimer Disease*

  2011cited by this paper
• Long term changes in phospho-APP and tau aggregation in the 3xTg-AD mice following cerebral ischemia.

  2011cited by this paper
• Blood–Brain Barrier Permeability Abnormalities in Vascular Cognitive Impairment

  2011cited by this paper
• Cerebrospinal fluid biomarkers of white matter lesions – cross‐sectional results from the LADIS study

  2010cited by this paper
• CSF Biomarkers Profile in CADASIL—A Model of Pure Vascular Dementia: Usefulness in Differential Diagnosis in the Dementia Disorder

  2010cited by this paper
• Quantification of myelin loss in frontal lobe white matter in vascular dementia, Alzheimer’s disease, and dementia with Lewy bodies

  2010cited by this paper
• Oligemic hypoperfusion differentially affects tau and amyloid-{beta}.

  2010cited by this paper
• Accumulation of tau induced in neurites by microglial proinflammatory mediators

  2009cited by this paper
• GSK-3β phosphorylation of functionally distinct tau isoforms has differential, but mild effects

  2009cited by this paper
• Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease.

  2009cited by this paper
• Alpha- and Gamma-Synuclein Proteins Are Present in Cerebrospinal Fluid and Are Increased in Aged Subjects with Neurodegenerative and Vascular Changes

  2008cited by this paper
• Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer’s disease

  2008cited by this paper
• The blood-brain barrier in health and chronic neurodegenerative disorders.

  2008cited by this paper
• Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition

  2008influential reference
• Quantification of Alzheimer pathology in ageing and dementia: age‐related accumulation of amyloid‐β(42) peptide in vascular dementia

  2006influential reference
• National Institute of Neurological Disorders and Stroke–Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards

  2006cited by this paper
• Molecular motors implicated in the axonal transport of tau and alpha-synuclein.

  2005cited by this paper
• Diagnosis and management of dementia with Lewy bodies

  2005cited by this paper
• Molecular motors implicated in the axonal transport of tau and α-synuclein

  2005cited by this paper
• Towards defining the neuropathological substrates of vascular dementia.

  2004influential reference
• Molecular Pathogenesis of Genetic and Inherited Diseases Induction of Inflammatory Mediators and Microglial Activation in Mice Transgenic for Mutant Human P301S Tau Protein

  2004cited by this paper
• Neuropathological stageing of Alzheimer-related changes

  2004cited by this paper
• Consortium to Establish a Registry for Alzheimer's Disease (CERAD)

  2002cited by this paper
• Loss of synaptic but not cytoskeletal proteins in the cerebellum of chronic schizophrenics.

  2002cited by this paper
• The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis.

  2002cited by this paper
• National Institute of Neurological Disorders and Stroke FIVE-YEAR STRATEGIC PLAN ON MINORITY HEALTH DISPARITIES

  2002cited by this paper
• Tau protein isoforms, phosphorylation and role in neurodegenerative disorders.

  2000cited by this paper
• Quantitation of amyloid-β peptides in biological milieu using a novel homogeneous time-resolved fluorescence (HTRF) assay

  2000cited by this paper
• Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease.

  2000influential reference
• The role of cerebral ischemia in Alzheimer's disease.

  2000cited by this paper
• Rapid Tau Protein Dephosphorylation and Differential Rephosphorylation during Cardiac Arrest-Induced Cerebral Ischemia and Reperfusion

  2000cited by this paper
• Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's disease.

  1999cited by this paper
• Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease

  1999cited by this paper
• Treatment of poor-risk neuroblastoma patients with high-dose chemotherapy and autologous peripheral stem cell rescue

  1997cited by this paper
• Changes in Phosphorylation of τ During Ischemia and Reperfusion in the Rabbit Spinal Cord

  1996cited by this paper
• Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease.

  1996cited by this paper
• Dementia with Lewy Bodies: What is the neuropathological basis of dementia associated with Lewy bodies?

  1996cited by this paper
• Alterations in tau protein metabolism during normal aging.

  1996cited by this paper
• Cerebral vessels in ageing and Alzheimer's disease.

  1996influential reference
• Tau protein directly interacts with the amyloid β-protein precursor: Implications for Alzheimer's disease

  1995cited by this paper
• Quantitative analysis of tau protein in paired helical filament preparations: implications for the role of tau protein phosphorylation in PHF assembly in Alzheimer's disease.

  1995cited by this paper
• A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele.

  1995cited by this paper
• Biochemical and anatomical redistribution of tau protein in Alzheimer's disease.

  1993cited by this paper
• Molecular characterization of the minimal protease resistant tau unit of the Alzheimer's disease paired helical filament.

  1993cited by this paper
• Selective precipitation of proteins from guanidine hydrochloride-containing solutions with ethanol.

  1991cited by this paper
• A68: a major subunit of paired helical filaments and derivatized forms of normal Tau.

  1991cited by this paper
• Measurement of distinct immunochemical presentations of tau protein in Alzheimer disease.

  1991cited by this paper
• The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)

  1991cited by this paper
• CAMDEX: A Standardised Instrument for the Diagnosis of Mental Disorder in the Elderly with Special Reference to the Early Detection of Dementia

  1986cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper

• The enigma of vascular dementia: current state and emerging perspectives.

  2026cites this paper
• Towards a better diagnosis and treatment of dementia: Identifying common and distinct neuropathological mechanisms in Alzheimer's and vascular dementia.

  2025cites this paper
• Biomarker pathway heterogeneity of amyloid‐positive individuals

  2024cites this paper
• Cerebral hypoperfusion reduces tau accumulation

  2024cites this paper
• Integrated transcriptome and metabolome analysis to investigate the mechanism of intranasal insulin treatment in a rat model of vascular dementia

  2023cites this paper
• Editorial: Novel mechanisms involved in aging and neurodegeneration: Seeking potential therapeutic targets for neurodegenerative diseases

  2022cites this paper
• Tubulin Isotypes and Posttranslational Modifications in Vascular Dementia and Alzheimer’s Disease

  2022cites this paper
• Tubulin and Tubulin Posttranslational Modifications in Alzheimer’s Disease and Vascular Dementia

  2021cites this paper
• Nasal Extracts from Patients with Alzheimer’s Disease Induce Tau Aggregates in a Cellular Model of Tau Propagation

  2021cites this paper
• Tetrahydroxy stilbene glycoside alleviated inflammatory damage by mitophagy via AMPK related PINK1/Parkin signaling pathway.

  2020cites this paper
• Differential protein expression in diverse brain areas of Parkinson’s and Alzheimer’s disease patients

  2020cites this paper
• Tau Biology

  2019cites this paper
• Genome-Wide Association Studies for Cerebrospinal Fluid Soluble TREM2 in Alzheimer’s Disease

  2019cites this paper
• Tau, Diabetes and Insulin.

  2019cites this paper
• A Novel Method Based on Linear Regression Model for Identify the Sensitivity of Quantitative Trait in ADNI Cohort

  2018cites this paper
• Genome-Wide Association and Mechanistic Studies Indicate That Immune Response Contributes to Alzheimer’s Disease Development

  2018cites this paper
• Tau pathology and neurochemical changes associated with memory dysfunction in an optimised murine model of global cerebral ischaemia ‐ A potential model for vascular dementia?

  2018cites this paper
• Evaluation of the Feasibility of Screening Tau Radiotracers Using an Amyloid Biomathematical Screening Methodology

  2018cites this paper
• Hippocampal Neurodegenerative Pathology in Post-stroke Dementia Compared to Other Dementias and Aging Controls

  2017influential citation
• Genome-wide association and interaction studies of CSF T-tau/Aβ42 ratio in ADNI cohort.

  2017cites this paper
• Analytical performance of reagent for assaying tau protein in human plasma and feasibility study screening neurodegenerative diseases

  2017cites this paper
• A Quantitative Analysis of Brain Soluble Tau and the Tau Secretion Factor

  2017cites this paper
• Meta‐analysis of synaptic pathology in Alzheimer's disease reveals selective molecular vesicular machinery vulnerability

  2016cites this paper
• Can microbiota research change our understanding of neurodegenerative diseases?

  2016cites this paper
• tau protein, ischemic injury and vascular dementia

  2015cites this paper
• Study on active ingredient and mechanism in preventing vascular dementia of Tianzhusan coming from Tujia medicine.

  2015cites this paper